Insider Buying: enVVeno Medical Corporation (NASDAQ:NVNO) Director Purchases 5,400 Shares of Stock

enVVeno Medical Corporation (NASDAQ:NVNO) Director Sanjay Shrivastava purchased 5,400 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were acquired at an average price of $2.90 per share, for a total transaction of $15,660.00. Following the purchase, the director now directly owns 9,288 shares of the company’s stock, valued at approximately $26,935.20. The trade was a 138.89 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

enVVeno Medical Stock Up 8.5 %

NVNO stock opened at $3.06 on Friday. enVVeno Medical Corporation has a 52 week low of $2.45 and a 52 week high of $6.97. The stock has a market capitalization of $53.66 million, a PE ratio of -2.37 and a beta of 1.22. The firm has a 50 day moving average of $3.19 and a 200 day moving average of $4.31.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). On average, equities research analysts expect that enVVeno Medical Corporation will post -1.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in enVVeno Medical by 7.8% during the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after buying an additional 10,902 shares in the last quarter. Corsair Capital Management L.P. purchased a new stake in shares of enVVeno Medical during the 3rd quarter worth about $390,000. Westside Investment Management Inc. grew its position in shares of enVVeno Medical by 128.0% during the 3rd quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock valued at $297,000 after acquiring an additional 49,613 shares during the period. Maven Securities LTD purchased a new position in shares of enVVeno Medical in the 3rd quarter valued at about $295,000. Finally, Hohimer Wealth Management LLC acquired a new position in enVVeno Medical in the 3rd quarter worth about $286,000. 34.71% of the stock is currently owned by hedge funds and other institutional investors.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®?, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).